Clinical Trial Update: Efficacy and Safety of Morning Versus Evening Intake of Simvast Controlled Release (CR) Tablet in Patients With Hyperlipidemia [Phase 3]

View source ↗

Summary

A Phase 3 trial evaluating morning versus evening dosing of simvastatin controlled-release for hyperlipidemia has completed, with focus on efficacy and safety.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hyperlipidemia

Drugs mentioned

• Simvastatin Controlled-Release Tablet (simvastatin)

Snippet

Sponsor: Hanmi Pharmaceutical Company Limited | Conditions: Hyperlipidemia | Phase 3 | Status: COMPLETED